NASDAQ:XERS

Xeris Pharmaceuticals Stock Forecast, Price & News

$3.95
-0.16 (-3.89 %)
(As of 06/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.85
$4.15
50-Day Range
$3.12
$4.16
52-Week Range
$2.45
$7.94
Volume2.36 million shs
Average Volume2.84 million shs
Market Capitalization$262.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84
30 days | 90 days | 365 days | Advanced Chart
Receive XERS News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Xeris Pharmaceuticals logo

About Xeris Pharmaceuticals

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.43 out of 5 stars

Medical Sector

693rd out of 2,101 stocks

Pharmaceutical Preparations Industry

338th out of 831 stocks

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions

Is Xeris Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Xeris Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XERS, but not buy additional shares or sell existing shares.
View analyst ratings for Xeris Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Xeris Pharmaceuticals?

Wall Street analysts have given Xeris Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Xeris Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Xeris Pharmaceuticals' next earnings date?

Xeris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Xeris Pharmaceuticals
.

How were Xeris Pharmaceuticals' earnings last quarter?

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) issued its earnings results on Thursday, May, 13th. The company reported ($0.30) EPS for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.01. The firm earned $8.05 million during the quarter, compared to analyst estimates of $7.57 million. Xeris Pharmaceuticals had a negative trailing twelve-month return on equity of 275.08% and a negative net margin of 302.93%.
View Xeris Pharmaceuticals' earnings history
.

How has Xeris Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Xeris Pharmaceuticals' stock was trading at $2.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XERS shares have increased by 77.9% and is now trading at $3.95.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for XERS?

3 brokerages have issued 1 year price targets for Xeris Pharmaceuticals' stock. Their forecasts range from $9.00 to $15.00. On average, they expect Xeris Pharmaceuticals' share price to reach $11.33 in the next year. This suggests a possible upside of 186.9% from the stock's current price.
View analysts' price targets for Xeris Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Xeris Pharmaceuticals' key executives?

Xeris Pharmaceuticals' management team includes the following people:
  • Mr. Paul R. Edick, Chairman & CEO (Age 65, Pay $1.09M)
  • Mr. John P. Shannon, Pres & COO (Age 59, Pay $776.08k)
  • Ms. Beth P. Hecht, Sr. VP, Gen. Counsel & Corp. Sec. (Age 57, Pay $588.29k)
  • Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 57)
  • Mr. Barry M. Deutsch, Chief Financial Officer (Age 56)
  • Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications
  • Dr. Kenneth E. Johnson Pharm.D., Pharm. D., Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs (Age 58)
  • Mr. Kevin McCulloch, Sr. VP of Global Operations & Bus. Devel.

Who are some of Xeris Pharmaceuticals' key competitors?

What other stocks do shareholders of Xeris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and OrganiGram (OGI).

When did Xeris Pharmaceuticals IPO?

(XERS) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Xeris Pharmaceuticals' stock symbol?

Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."

Who are Xeris Pharmaceuticals' major shareholders?

Xeris Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.30%), Redmile Group LLC (2.87%), Renaissance Technologies LLC (1.77%), D. E. Shaw & Co. Inc. (1.65%), Geode Capital Management LLC (1.31%) and Deltec Asset Management LLC (0.99%). Company insiders that own Xeris Pharmaceuticals stock include John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski.
View institutional ownership trends for Xeris Pharmaceuticals
.

Which institutional investors are selling Xeris Pharmaceuticals stock?

XERS stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Goldman Sachs Group Inc., Deltec Asset Management LLC, Miracle Mile Advisors LLC, TownSquare Capital LLC, Nuveen Asset Management LLC, Searle & CO., and Lido Advisors LLC.
View insider buying and selling activity for Xeris Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Xeris Pharmaceuticals stock?

XERS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Tamarack Advisers LP, Morgan Stanley, UBS Group AG, Millennium Management LLC, BlackRock Inc., D. E. Shaw & Co. Inc., and GSA Capital Partners LLP. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include John Patrick Shannon Jr, and Paul R Edick.
View insider buying and selling activity for Xeris Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Xeris Pharmaceuticals?

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xeris Pharmaceuticals' stock price today?

One share of XERS stock can currently be purchased for approximately $3.95.

How much money does Xeris Pharmaceuticals make?

Xeris Pharmaceuticals has a market capitalization of $262.13 million and generates $20.16 million in revenue each year. The company earns $-91,140,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

How many employees does Xeris Pharmaceuticals have?

Xeris Pharmaceuticals employs 209 workers across the globe.

What is Xeris Pharmaceuticals' official website?

The official website for Xeris Pharmaceuticals is www.xerispharma.com.

Where are Xeris Pharmaceuticals' headquarters?

Xeris Pharmaceuticals is headquartered at 180 N. LaSalle Street Suite 1810, Chicago IL, 60601.

How can I contact Xeris Pharmaceuticals?

Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]


This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.